Burstein will join the audit committee and serve as its chair.
Burstein most recently served as senior vice president of finance and principal financial officer at Loxo Oncology, Inc., until its acquisition by Eli Lilly and company in January 2019.
From 2006 to 2015, Burstein held roles of increasing responsibility in finance at Acorda Therapeutics, Inc., and ultimately served as vice president of finance for the company from 2010 to 2015.
Before that, she worked on the finance team at Eyetech Pharmaceuticals, Inc., which is currently a subsidiary of Valeant Pharmaceuticals International, Inc.
Earlier in her career, Burstein worked in the finance departments at several companies and in public accounting. She holds a B.S. in business administration and her MBA in accounting, both from the State University of New York at Buffalo, and holds a CPA license in New York.
Stoke Therapeutics is a biotechnology company that is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels.
Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health.
These diseases, in which loss of approximately 50 % of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies.
Stoke was launched with investments by Apple Tree Partners and has raised a total of over USD 130m to date through two financing rounds. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886